You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the LUPKYNIS (voclosporin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR LUPKYNIS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LUPKYNIS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05306873 ↗ Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2022-04-18 The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients. Treatment effects will be evaluated within the individual immunologically-homogenous subsets defined at screening. This study will also explore and compare pre-randomization gene expression patterns among responders and non-responders to MMF and MMF plus voclosporin, use comprehensive immunophenotyping to study the immunologic changes that accompany treatment- induced disease improvement and to better understand immunologic changes associated with the loss of clinical response.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LUPKYNIS

Condition Name

Condition Name for LUPKYNIS
Intervention Trials
Systemic Lupus Erythematosus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LUPKYNIS
Intervention Trials
Lupus Erythematosus, Systemic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LUPKYNIS

Trials by Country

Trials by Country for LUPKYNIS
Location Trials
United States 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LUPKYNIS
Location Trials
Pennsylvania 1
Oklahoma 1
North Carolina 1
New York 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LUPKYNIS

Clinical Trial Phase

Clinical Trial Phase for LUPKYNIS
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LUPKYNIS
Clinical Trial Phase Trials
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LUPKYNIS

Sponsor Name

Sponsor Name for LUPKYNIS
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LUPKYNIS
Sponsor Trials
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.